Truist Securities Maintains Buy on AdaptHealth, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has maintained a Buy rating on AdaptHealth (NASDAQ:AHCO) and increased the price target from $11 to $13.
February 28, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on AdaptHealth and raised the price target from $11 to $13.
The increase in price target by a reputable analyst like David Macdonald suggests a positive outlook on AdaptHealth's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100